| ||
| Peregrine Says Bavituximab Combination Promising In Mid-stage Lung Cancer Study RTT News (RTTNews) - Peregrine Pharmaceuticals, Inc. (PPHM: News ), a clinical-stage biopharmaceutical company, Wednesday announced promising median overall survival of 12.4 months from a Phase II clinical trial evaluating non-small cell lung cancer drug ... See all stories on this topic » | ||
| ASCO 2011: Crizotinib Continues to Show Responses in Lung Cancer Patients Cancer Network By Anna Azvolinsky, PhD | June 15, 2011 An ongoing Phase II trial of patients with non-small cell lung cancer (NSCLC) that harbor a specific mutation in the anaplastic lymphoma kinase (ALK) gene reported at ASCO that ~80% of trial participants have ... See all stories on this topic » | ||
| European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer Internal Medicine News Digital Network First-line erlotinib (Tarceva) improved the primary end point of progression-free survival from 5.2 months with standard platinum-based chemotherapy to 9.4 months in white patients who had advanced non-small cell lung cancer (NSCLC) with epidermal ... See all stories on this topic » | ||
| Peregrine says lung cancer drug extended survival Forbes The results come from a mid-stage study of 49 patients with untreated, advanced non-small cell lung cancer. In addition to bavituximab, Peregrine said the patients were treated with the chemotherapy drugs carboplatin and paclitaxel. See all stories on this topic » | ||
| Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II ... Marketwire (press release) ... promising median overall survival (MOS) of 12.4 months from a Phase II clinical trial evaluating bavituximab plus carboplatin and paclitaxel in patients with previously untreated, locally-advanced or metastatic non-small cell lung cancer (NSCLC). ... See all stories on this topic » | ||
| Endocyte Names Binh Nguyen, MD, Ph.D. as Vice President of Clinical Affairs GlobeNewsWire (press release) Dr. Nguyen's work contributed to the global approvals of Alimta® and Gemzar® in six indications: mesothelioma, first and second-line non-small cell lung cancer, as well as pancreatic, bladder, breast and ovarian cancers. Dr. Nguyen received his Ph.D. ... See all stories on this topic » |
| ||
| Anticancer Effect Of Mushrooms Found in Grocery Stores ... By Alton Parrish To date, 20 patients with advanced nonsmall cell lung cancer have received treatment with escalating doses of MM-10-001, from 5 to 10 to 20 mg, over 28 days. No severe adverse events were reported. Two patients reported grade 2 fatigue, ... Nano Patents and Innovations | ||
| Sanofi's Iniparib Fails Phase III Study, but Firm Investigating ... The company will continue to study iniparib in breast, non-small cell lung, and ovarian cancer. Not Your Typical PARP Inhibitor. The news that Sanofi will conduct genetic analysis to attempt to identify best responders for iniparib ... |
| ||
| non small cell lung cancer | Archive Directory | Azoomed – Submit ... Azoomed.com: A source for guidance, learning, research and entertainment in thousands of subjects. www.azoomed.com/keywords/non-small-cell-lung-cancer/ |
This once a day Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment